top of page

Synendos Therapeutics

First-in-class endocannabinoid modulators to restore natural functioning of the brain in CNS disorders.
OVERVIEW

Synendos is a clinical stage, neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric disorders. We utilise the modulation of a new drug target in the endocannabinoid system (ECS) that enables restoration of the natural functioning of the brain. Synendos’ lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). SERIs represent first in class, new chemical entities that modulate the ECS through a self-limiting mode of action with the potential to deliver meaningful benefits to patients. 

home testo_modificato.jpg

Synendos' current focus is on anxiety and mood-related diseases characterized by an endocannabinoid deficiency and with high unmet medical need such as post-traumatic stress disorder (PTSD). In January 2024 Synendos received authorization to begin clinical studies with SYT-510 and Phase 1 was initiated in February of that year.

​

Synendos closed a Series A round of CHF 24m in April 2021 with a strong syndicate of investors including Kurma Partners, Sunstone Life Science Ventures, Ysios Capital and Bernina BioInvest. In addition, Synendos has raised CHF 4m in grant funding from a variety of sources that have provided a firm validation of the technology, approach and potential success of the company.

​

Synendos is a spin-out from the University of Bern and retains access to the extensive expertise of the ECS within the group of Prof Jürg Gertsch.

​

All of the assets and targets relevant to the company are protected by a robust series of patents filed or granted in all major markets.

​

 

INNOVATIVE APPROACH AIMED AT PROVIDING SAFER AND MORE EFFECTIVE THERAPIES FOR CNS DISORDERS
home approach_modificato.jpg

The endocannabinoid system is a key neuromodulator system in the CNS and represents a promising therapeutic target for a wide range of CNS diseases characterized by insufficient endocannabinoid signalling (deficiency).

 

Selective endocannabinoid reuptake inhibitors (SERIs) can restore normal endocannabinoid tone through the modulation of a newly identified drug target responsible of endocannabinoid cell reuptake.

SERIs can exert pro-homeostatic effects on different neuronal circuits by acting with a self-limiting mechanism of action. At Synendos, we advance the preclinical and clinical development of SYT-510 and two other possible follow up compounds.

​

LATEST NEWS
Artboard 9_3x.png
Need more details? Contact us
​

We are here to assist. Contact us by email or via our social media channels.

bottom of page